Free Trial
OTCMKTS:SGIOY

Shionogi & Co., Ltd. Unsponsored ADR 5/13/2024 Earnings Report

Shionogi & Co., Ltd. Unsponsored ADR logo
$9.11 +0.17 (+1.90%)
As of 09/19/2025 03:59 PM Eastern

Shionogi & Co., Ltd. Unsponsored ADR EPS Results

Actual EPS
$0.21
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Shionogi & Co., Ltd. Unsponsored ADR Revenue Results

Actual Revenue
$662.08 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Shionogi & Co., Ltd. Unsponsored ADR Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Shionogi & Co., Ltd. Unsponsored ADR's next earnings date is estimated for Monday, October 27, 2025, based on past reporting schedules.

Conference Call Resources

Shionogi & Co., Ltd. Unsponsored ADR Earnings Headlines

Out of 18,347 Cryptocurrencies... This is the ONLY One
The Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should buy in this market, this token might just be it.tc pixel
See More Shionogi & Co., Ltd. Unsponsored ADR Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Shionogi & Co., Ltd. Unsponsored ADR? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Shionogi & Co., Ltd. Unsponsored ADR and other key companies, straight to your email.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co., Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.

The company’s product portfolio spans both established and innovative therapies. Shionogi markets cefiderocol (Fetroja) for complicated urinary tract infections, an investigational oral antiviral for COVID-19, and a range of influenza treatments. It also collaborates with international partners on HIV integrase inhibitors and oncology agents, leveraging strategic alliances to accelerate global development and distribution.

Headquartered in Osaka, Shionogi maintains research facilities and subsidiaries across Asia, North America and Europe. Its network of laboratories focuses on discovery science, translational research and clinical development, while manufacturing sites in Japan and abroad ensure supply chain resilience and regulatory compliance in multiple regions.

Governed by a board of directors and led by a President & Representative Director, Shionogi continues to invest heavily in R&D, with a pipeline targeting antimicrobial resistance, metabolic diseases and novel immunotherapies. Its unsponsored American depositary receipt trades on the OTC Market under the ticker SGIOY, providing U.S. investors access to its evolving business.

View Shionogi & Co., Ltd. Unsponsored ADR Profile

More Earnings Resources from MarketBeat